Single-center experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression

Clin Transplant. 2022 Aug;36(8):e14752. doi: 10.1111/ctr.14752. Epub 2022 Jun 28.

Authors

Krista Mecadon¹, Panos Arvanitis², Dimitrios Farmakiotis³, Ralph Rogers³

Affiliations

¹ Department of Pharmacy, Rhode Island Hospital, Rhode Island, USA.
² Warren Alpert Medical School of Brown University, Rhode Island, USA.
³ Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Rhode Island, USA.

PMID: 35713302
DOI: 10.1111/ctr.14752

No abstract available

Publication types

Letter

MeSH terms

Graft Rejection / etiology
Graft Rejection / prevention & control
Humans
Immunosuppression Therapy
Immunosuppressive Agents / therapeutic use
Kidney Transplantation*
Ritonavir / therapeutic use
Tacrolimus* / therapeutic use
Transplant Recipients

Substances

Immunosuppressive Agents
Ritonavir
Tacrolimus